Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
By K. Stenlöf, W. Cefalu, Kyoung-Ah Kim, M. Alba, K. Usiskin, C. Tong, W. Canovatchel, G. Meininger. Diabetes, obesity and metabolism, 2013
617 citations recorded by the source corpus.
Canagliflozin is a sodium glucose co‐transporter 2 inhibitor in development for type 2 diabetes mellitus (T2DM). The efficacy and safety of canagliflozin were evaluated in subjects with T2DM inadequately controlled with diet and exercise.
Subfields: Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/79ac38d23dde4f11c6f464d726545bb425d7fc4f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
- John B. Buse
- E. Ferrannini
- M. Nauck
- Juan José Marín-Peñalver
- Cristina Sevillano-Collantes
- Iciar Martín-Timón
- F. J. del Cañizo-Gómez
- Silvio E. Inzucchi
In Surgery
Citations in the corpus
- Update on the treatment of type 2 diabetes mellitus. (2016, background): “It is an effective drug in monotherapy and after 26 wk of treatment with canagliflozin 100 mg and 300 mg once daily significantly reduced HbA1c (0.77% and 1.03% respectively) in patients with T2DM not controlled with diet and exercise compared to placebo (0.14%, P 0.001) [147] .”
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2014, background): “Additional potential advantages include modest weight loss (;2 kg, stabilizing over 6– 12 months) and consistent lowering of systolic and diastolic blood pressure in the order of ;2–4/;1–2 mmHg (7,8,15).”
- Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2015, background): “Additional potential advantages include modest weight loss (~2 kg, stabilising over 6– 12 months) and consistent lowering of systolic and diastolic blood pressure in the order of ~2–4/~1–2 mmHg [7, 8, 15].”